Baker Botts Advises Viracorp On Partnership with Lancaster University to Produce New Nasal COVID-19 Vaccine
Deal Description: On November 12, 2021, ViraCorp, a British biomedical firm, announced a partnership with Lancaster University to develop a unique nasal COVID-19 vaccine which attacks the virus at its entry point into the body.
Under its subsidiary ViraVac, ViraCorp’s new vaccine is based on the work of Lancaster Molecular Virologist Dr Muhammad Munir, a pioneer of needleless and next-generation COVID-19 vaccines. The ViraVac vaccine will provide a cost-effective and easily administered alternative to solutions currently on the market.
The Viravac vaccine is an intranasal vaccine, which induces a special type of antibodies in the respiratory tract as the first line of defense against the virus. It is hoped that the nasal method will improve the pace of the global vaccine rollout, as well as remove the need for extensive training that is required for delivering vaccines via intramuscular injections.
Baker Botts advised Viracorp on preparing the development and collaboration agreement.
Baker Botts Lawyers/Office Involved:
Corporate: David Ramm (Partner, London), Sonia Namutebi (Associate, London).
ABOUT BAKER BOTTS L.L.P.
Baker Botts is an international law firm whose lawyers practice throughout a network of offices around the globe. Based on our experience and knowledge of our clients' industries, we are recognized as a leading firm in the energy, technology and life sciences sectors. Since 1840, we have provided creative and effective legal solutions for our clients while demonstrating an unrelenting commitment to excellence. For more information, please visit bakerbotts.com.
